Luteolinidin

Luteolinidin

SCHEMBL676808

Oc1cc(O)c2ccc(-c3ccc(O)c(O)c3)[o+]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CD38 P28907 11/20 1.00
F2 P00734 1/20 0.62
NR1H2 P55055 1/20 0.62
NR1H3 Q13133 1/20 0.62
GLO1 Q04760 5/20 0.60
SNCA P37840 3/20 0.60
DPP4 P27487 2/20 0.60
OR51E2 Q9H255 2/20 0.49
EGFR P00533 2/20 0.45
KDR P35968 2/20 0.45
EP300 Q09472 2/20 0.45
CREBBP Q92793 2/20 0.45
APP P05067 3/20 0.42
ALOX5 P09917 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Luteolinidin SCHEMBL30159678 1.00 CD38 (1.00) CD38F2NR1H2NR1H3GLO1
Luteolinidin SCHEMBL676807 0.98 CD38 (0.97) CD38F2NR1H2NR1H3GLO1
SCHEMBL7045086 0.89 CD38 (0.79) CD38F2NR1H2NR1H3GLO1
SCHEMBL5692415 0.86 CD38 (0.76) CD38F2NR1H2NR1H3GLO1
Hydrochloric Acid SCHEMBL29392598 0.85 CD38 (0.73) CD38F2NR1H2NR1H3GLO1
Hydrochloric Acid SCHEMBL1366891 0.85 CD38 (0.73) CD38F2NR1H2NR1H3GLO1
Hydrochloric Acid SCHEMBL29413086 0.85 CD38 (0.73) CD38F2NR1H2NR1H3GLO1
SCHEMBL6131745 0.85 CD38 (0.73) CD38F2NR1H2NR1H3GLO1
Hydrochloric Acid SCHEMBL6131747 0.83 CD38 (0.71) CD38F2NR1H2NR1H3GLO1
Hydrochloric Acid SCHEMBL11317960 0.83 CD38 (0.71) CD38F2NR1H2NR1H3GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 968 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260090969-A1 COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS Nuchido Limited (GB) 2026-04-02 US claimed
EP-4622686-A1 SPRAY PATCH COMPOSITION, PROCESS FOR PREPARING IT AND KIT Fondazione Istituto Italiano di Tecnologia (IT) 2025-10-01 EP claimed
WO-2025093707-A1 METHOD FOR SUPPRESSING CAR-T CELLS UNRESPONSIVENESS FOR IMPROVING CANCER IMMUNOTHERAPY Université de Lausanne (CH) 2025-05-08 WO claimed
US-20250064094-A1 COMPOSITIONS FOR FOOD COLORING AND ANTIOXIDANT SUPPLEMENTATION DERIVED FROM SORGHUM RedLeaf Biologics, Inc. (US) 2025-02-27 US claimed
EP-4472625-A1 COMPOSITIONS FOR FOOD COLORING AND ANTIOXIDANT SUPPLEMENTATION DERIVED FROM SORGHUM Redleaf Biologics, Inc. (US) 2024-12-11 EP claimed
WO-2024248183-A1 HAIR-PROTECTING COMPOSITION AND HAIR CARE PRODUCT COMPRISING SAME 주식회사 모다바이오 2024-12-05 WO claimed
EP-4426338-A2 CD38 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Intellia Therapeutics, Inc. (US) 2024-09-11 EP claimed
WO-2024110911-A1 SPRAY PATCH COMPOSITION, PROCESS FOR PREPARING IT AND KIT FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2024-05-30 WO claimed
US-20230355769-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS Natural Extraction Systems, LLC (US) 2023-11-09 US claimed
US-20230338331-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS Natural Extraction Systems, LLC (US) 2023-10-26 US claimed
US-6471949-B2 COSMETICS; FOR ARTIFICIALLY COLORING THE SKIN L'OREAL S.A. (FR) 2002-10-29 US claimed
US-20020064507-A1 Compositions comprising at least one UV screening agent and at least one flavylium salt which is unsubstituted in position 3, for coloring the skin, and uses thereof L'OREAL S.A. (FR) 2002-05-30 US claimed
US-20020051755-A1 Composition comprising at least one self-tanning agent chosen from monocarbonyl and polycarbonyl compounds and a flavylium salt compound which is unsubstituted in position 3, for coloring the skin, and uses thereof L'OREAL S.A. (FR) 2002-05-02 US claimed
US-20020048555-A1 Artificial tanning compositions comprising flavylium salts SOCIETE L'OREAL S.A. (FR) 2002-04-25 US claimed
US-20020048556-A1 Compositions for coloring the skin comprising at least one flavylium salt which is unsubstituted in position 3 and at least one organomodified silicone L'OREAL S.A (FR) 2002-04-25 US claimed
WO-2002024212-A1 CHOLESTEROL IN BLOOD-LOWERING COMPOSITION AND ITS COMPLEX, AND METHOD FOR PREPARING THEM ULTIMATE LIFE TECHNOLOGY CO., LTD. (KR) 2002-03-28 WO claimed
WO-1997041137-A1 USE OF ANTHOCYANIDIN AND ANTHOCYANIDIN DERIVATIVES UNIFOB (NO) 1997-11-06 WO claimed
EP-0785790-A1 USE OF ANTHOCYANIDIN AND DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS UNIFOB STIFTELSEN UNIVERSITETSFORSKNING BERGEN (NO) 1997-07-30 EP claimed
WO-1996011692-A9 USE OF ANTHOCYANIDIN AND DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS 1996-06-20 WO claimed
WO-1996011692-A1 USE OF ANTHOCYANIDIN AND DERIVATIVES FOR TREATMENT OF RETROVIRAL INFECTIONS UNIFOB STIFTELSEN UNIVERSITETSFORSKNING BERGEN (NO) 1996-04-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260090969-A1 COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS NLN, TFAM, CYP27B1 CD38 974/4885F2 3752/4885NR1H2 449/4885
US-20230355769-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS CNR2, CNR1, UGT8 CD38 2308/4885F2 50/4885NR1H2 453/4885
US-20230338331-A1 COMPOSITIONS, CONTAINERS, AND METHODS RELATED TO FLAVYLIUM EXCIPIENTS CNR2, CNR1, UGT8 CD38 2308/4885F2 50/4885NR1H2 453/4885
US-20020064507-A1 Compositions comprising at least one UV screening agent and at least one flavylium salt which is unsubstituted in position 3, for coloring the skin, and uses thereof TYR, CUTA, POLR1C CD38 4238/4885F2 229/4885NR1H2 2550/4885
US-20020048556-A1 Compositions for coloring the skin comprising at least one flavylium salt which is unsubstituted in position 3 and at least one organomodified silicone CUTA, LPO, TYR CD38 4862/4885F2 422/4885NR1H2 272/4885
US-20020048555-A1 Artificial tanning compositions comprising flavylium salts ADH7, TYR, HADHB CD38 3003/4885F2 564/4885NR1H2 2600/4885
US-20020051755-A1 Composition comprising at least one self-tanning agent chosen from monocarbonyl and polycarbonyl compounds and a flavylium salt compound which is unsubstituted in position 3, for coloring the skin, and uses thereof TYR, CUTA, MITF CD38 3110/4885F2 870/4885NR1H2 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.